Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference.
| CAMBRIDGE, Mass., Sept. 1, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference. The hybrid conference will take place September 12–14, 2022.
The presentation will be available on-demand beginning September 12, 2022 through the Investors section of Akebia’s website at https://ir.akebia.com for approximately 90 days. About Akebia Therapeutics Akebia Therapeutics Contact
SOURCE Akebia Therapeutics | ||
Company Codes: NASDAQ-NMS:AKBA |
View original content to download multimedia:
